Evidence map›Paper›PMID 40999310›Full record

ArticleBulletin of experimental biology and medicine2025

Clinical and Morphological Features of gPALB2-Associated Breast Cancer in the Russian Population.

V A Fedko, E V Artamonova, A M Stroganova, V A Mileyko, T S Lisitsa, A K Novikov, E I Kovalenko

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

V A FedkoN. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Moscow, Russia. v.a.fedko@yandex.ru.
E V ArtamonovaN. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Moscow, Russia.
A M StroganovaN. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Moscow, Russia.
V A MileykoOncodiagnostics ATLAS LLC, Moscow, Russia.
T S LisitsaN. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Moscow, Russia.
A K NovikovPirogov Russian National Research Medical University (Pirogov University), Ministry of Health of the Russian Federation, Moscow, Russia.
E I KovalenkoN. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The analysis included 3,800 cases of breast cancer. Next-generation sequencing (NGS) of DNA extracted from peripheral blood leukocytes revealed mutations in the gPALB2 gene in 39 (1.03%) patients. The most frequent mutations were c.509_510del (25.64%), c.1592del (20.51%), and c.172_175del (10.26%). The predominant histological variant was invasive ductal carcinoma (84.62%) with moderate differentiation (G2) (48.72%). In most cases, luminal HER2

Indexed as

Breast NeoplasmsCarcinoma, Ductal, BreastAdultAgedErb-b2 Receptor Tyrosine KinasesFemaleHigh-Throughput Nucleotide SequencingHumansMiddle AgedMutationNeoadjuvant TherapyReceptors, EstrogenRussiaERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenBreast cancer, DNA repair genesGermline mutationHomologous recombinationPALB2

Identifiers

PMID40999310

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.